Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine
Arianna Dal Buono, Roberto Gabbiadini, Ludovico Alfarone, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1735-1735
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

The role of Th17 cells in inflammatory bowel disease and the research progress
Lu Chen, Guangcong Ruan, Yi Cheng, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 87
Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology
Piotr Eder, Michał Łodyga, Magdalena Gawron-Kiszka, et al.
Gastroenterology Review (2023) Vol. 18, Iss. 1, pp. 1-42
Open Access | Times Cited: 30
Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis
Bruce E. Sands, Stefan Schreiber, Irina Blumenstein, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 12, pp. 2012-2025
Open Access | Times Cited: 27
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
Silvio Danese, Remo Panaccione, María T. Abreu, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 2, pp. 264-274
Open Access | Times Cited: 26
Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Virginia Solitano, Sudheer K. Vuyyuru, John K MacDonald, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 11, pp. 1800-1816
Closed Access | Times Cited: 24
Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer
Keila S. Espinoza, Ashley J. Snider
Cancers (2024) Vol. 16, Iss. 4, pp. 789-789
Open Access | Times Cited: 11
Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
Ole Haagen Nielsen, Theresa Louise Boye, John Gubatan, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108402-108402
Open Access | Times Cited: 22
Treatment strategies in inflammatory bowel diseases
Andreas Stallmach, Raja Atreya, Philip C. Grunert, et al.
Deutsches Ärzteblatt international (2023)
Open Access | Times Cited: 17
Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials
Sara Massironi, Federica Furfaro, Sarah Bencardino, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 761-787
Open Access | Times Cited: 7
Predictive, preventive and personalised approach as a conceptual and technological innovation in primary and secondary care of inflammatory bowel disease benefiting affected individuals and populations
Laura Arosa, Miguel Camba-Gómez, Olga Golubnitschaja, et al.
The EPMA Journal (2024) Vol. 15, Iss. 1, pp. 111-123
Open Access | Times Cited: 6
The role of sphingosine-1-phosphate in autophagy and related disorders
Siqi Xiao, Kaixin Peng, C.-L. Li, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Transmembrane protein CD69 acts as an S1PR1 agonist
Hongwen Chen, Qin Yu, Marissa Chou, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 14
Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model
Leo Heinig, Markus Kipp
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 16093-16093
Open Access | Times Cited: 20
Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review
Anders Forss, Paulina Flis, Adonis Sotoodeh, et al.
Scandinavian Journal of Gastroenterology (2024) Vol. 59, Iss. 7, pp. 821-829
Open Access | Times Cited: 4
The Potential Capacities of FTY720: Novel Therapeutic Functions, Targets, and Mechanisms against Diseases
Juan Liu, Lu Zhang, Le Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117508-117508
Open Access
A Comprehensive Review of Small Molecules, Targets, and Pathways in Ulcerative Colitis Treatment
Xiaoxuan Cai, Yi-Han Huang, Yang-Chi-Dung Lin, et al.
European Journal of Medicinal Chemistry (2025) Vol. 291, pp. 117645-117645
Closed Access
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials
Panu Wetwittayakhlang, Talat Bessissow, Péter L. Lakatos
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 1, pp. 19-34
Closed Access | Times Cited: 3
Exploring Microbial Metabolite Receptors in Inflammatory Bowel Disease: An In Silico Analysis of Their Potential Role in Inflammation and Fibrosis
Michail Spathakis, Nikolas Dovrolis, Eirini Filidou, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 492-492
Open Access | Times Cited: 3
Development and validation of stability-indicating method of etrasimod by HPLC/DAD/MS/MS technique with greenness profiling
Jelena Kovačić, Daniela Amidžić Klarić, Nikša Turk, et al.
Heliyon (2024) Vol. 10, Iss. 13, pp. e34066-e34066
Open Access | Times Cited: 2
Targeting mucosal healing in Crohn’s disease: efficacy of novel pathways and therapeutic targets
Lucia Centanni, Sarah Bencardino, Ferdinando D’Amico, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 11, pp. 963-978
Closed Access | Times Cited: 2
Antibodies targeting the tumor necrosis factor (TNF) -like ligand 1A (TL1A) in Inflammatory Bowel Disease – a new kid on the (biologics) block?
Daniel Schweckendiek, Gerhard Rogler
Digestion (2024), pp. 1-8
Open Access | Times Cited: 1
Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial
Hong Zhang, Qianqian Li, Cuiyun Li, et al.
The Lancet Rheumatology (2024)
Closed Access | Times Cited: 1
Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Giovanni Pallio
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2466-2466
Open Access | Times Cited: 3
Oral small molecule agents in management of ulcerative colitis: fact or fancy
Benan Kasapoğlu, Atilla Ertan
TURKISH JOURNAL OF MEDICAL SCIENCES (2023) Vol. 53, Iss. 6, pp. 1526-1536
Open Access | Times Cited: 2
Expression of sphingosine-1-phosphate receptor 1 in neuroinflammation of canine brains
Taesik Yun, Sanggu Kim, Yoonhoi Koo, et al.
Topics in companion animal medicine (2024) Vol. 60, pp. 100847-100847
Closed Access
Page 1 - Next Page

Scroll to top